醫思健康(02138.HK)完成先舊後新配股 淨籌2.49億港元
格隆匯7月20日丨醫思健康(02138.HK)宣佈,配售事項及認購事項的條件已獲達成,而配售事項及認購事項已分別於2021年7月9日及2021年7月19日落實完成。配售代理已按配售價每股配售股份 14.50港元成功將所有 2797.24萬股配售股份配售予鄭志剛博士,太平紳士(以個人名義投資)及Aspex Master Fund("Aspex"),而根據該協議的條款及條件,賣方已按認購價每股認購股份14.50 港元認購合共 1721.38萬股認購股份。
公司收到認購事項所得款項淨額總額約2.488億港元,並擬將其用於(i) 擴大集團於中國香港及中國大灣區的診所網絡;(ii) 併購;及(iii) 集團的一般企業用途。
據悉,配售股份已配售予鄭志剛博士,太平紳士(以個人名義投資)及 Aspex。鄭志剛博士,太平紳士為一名文化企業家及一名個人投資者,而 Aspex 為一間於開曼羣島註冊成立的獲豁免有限公司,以私人投資基金形式營運,由 AspexManagement (HK) Limited("Aspex Management")管理。Aspex Management 為一間於香港成立的持牌法團,可根據證券及期貨條例於香港從事第 9 類(提供資產管理)受規管活動,並擔任 Aspex 的投資經理。Aspex 的投資目標乃為透過由下而上、深入研究、以基本因素主導的股權投資策略(集中於泛亞地區或主力於泛亞地區經營的公司),以在中長線方面取得吸引的絕對回報。Aspex 的投資者包括世界一流的大學捐贈基金、非牟利基金會、單一家族辦公室、主權財富基金、組合型基金及全球外各地的委外投資辦公室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.